Merck to discontinue phase 3 KEYNOTE-991 trial of Keytruda in combo with enzalutamide and ADT to treat mHSPC

Merck, known as MSD outside of the United States and Canada, announced that it will stop the phase 3 KEYNOTE-991 trial investigating Keytruda, Merck